
CAC2 Childhood Cancer Community News Digest (October 24-30)
Assorted News from the Last Week: CBS “Sunday Morning” contributor Kelefa Sanneh talked with CAC2 Members Kari and Tom Whitehead and their daughter Emily about

Assorted News from the Last Week: CBS “Sunday Morning” contributor Kelefa Sanneh talked with CAC2 Members Kari and Tom Whitehead and their daughter Emily about

Assorted News from the Last Week: Nearly one in four families of pediatric patients with acute lymphoblastic leukemia (ALL) enrolled in a clinical trial experienced

Assorted News from the Last Week: Pedmark (sodium thiosulfate) is now available to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1

Assorted News from the Last Week: Helping kids manage fear and anxiety when they have a serious illness Public sharing of pediatric brain cancer presentation

Assorted News from the Last Week: Making transformative advances against childhood cancer: A conversation with Dr. Doug Hawkins The FDA has approved sodium thiosulfate (Pedmark)

Assorted News from the Last Week: The FDA has approved sodium thiosulfate (Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients

Assorted News from the Last Week: Supporting Children and Families Through a Cancer Diagnosis by Child Life Specialist Nicolle Bengtson. Nearly 20 years since her

Assorted News from the Last Two Weeks: National Cancer Institute’s CCDI Molecular Characterization Initiative adds rare tumors. Study provides first in-depth look at major mix-ups

Children, adolescents, and young adults (AYAs) with newly diagnosed rare tumors are now eligible to enroll in the CCDI Molecular Characterization Initiative. Rare tumors are

Assorted News from the Last Two Weeks: The Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for the treatment of children aged 1 year or